Santen Pharmaceutical Future Growth
Future criteria checks 1/6
Santen Pharmaceutical's revenue is forecast to decline at 1.8% per annum while its annual earnings are expected to grow at 8.3% per year. EPS is expected to grow by 8.8% per annum. Return on equity is forecast to be 10.3% in 3 years.
Key information
8.3%
Earnings growth rate
8.8%
EPS growth rate
Pharmaceuticals earnings growth | 13.7% |
Revenue growth rate | -1.8% |
Future return on equity | 10.3% |
Analyst coverage | Good |
Last updated | 03 Jul 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 288,300 | 36,767 | 38,054 | 54,700 | 6 |
3/31/2026 | 289,661 | 35,510 | 43,904 | 58,567 | 9 |
3/31/2025 | 293,094 | 33,404 | 42,150 | 58,533 | 9 |
3/31/2024 | 301,965 | 26,642 | 62,758 | 72,649 | N/A |
12/31/2023 | 302,084 | 27,714 | 58,150 | 68,107 | N/A |
9/30/2023 | 295,928 | 26,364 | 33,466 | 46,547 | N/A |
6/30/2023 | 285,893 | -11,205 | 15,996 | 37,272 | N/A |
3/31/2023 | 279,037 | -14,955 | 12,559 | 37,147 | N/A |
12/31/2022 | 270,242 | -8,195 | 7,347 | 43,335 | N/A |
9/30/2022 | 266,413 | -9,133 | 17 | 37,279 | N/A |
6/30/2022 | 266,804 | 26,533 | 8,572 | 45,922 | N/A |
3/31/2022 | 266,257 | 27,212 | 10,202 | 46,043 | N/A |
12/31/2021 | 263,620 | 5,056 | 22,775 | 46,172 | N/A |
9/30/2021 | 259,459 | 7,319 | 22,195 | 47,476 | N/A |
6/30/2021 | 257,028 | 7,978 | 13,713 | 33,903 | N/A |
3/31/2021 | 249,605 | 6,826 | 15,004 | 38,808 | N/A |
12/31/2020 | 241,015 | 24,430 | 13,214 | 36,409 | N/A |
9/30/2020 | 241,685 | 24,279 | 16,958 | 34,787 | N/A |
6/30/2020 | 239,982 | 23,404 | 26,917 | 42,393 | N/A |
3/31/2020 | 241,555 | 23,616 | 30,719 | 39,947 | N/A |
12/31/2019 | 243,142 | 28,876 | 28,909 | 37,562 | N/A |
9/30/2019 | 238,457 | 30,721 | 30,088 | 39,233 | N/A |
6/30/2019 | 236,679 | 31,498 | 32,229 | 41,100 | N/A |
3/31/2019 | 234,026 | 31,953 | 24,561 | 32,894 | N/A |
12/31/2018 | 229,560 | 31,291 | 26,462 | 36,492 | N/A |
9/30/2018 | 228,512 | 34,370 | 28,786 | 38,360 | N/A |
6/30/2018 | 225,477 | 33,083 | 24,239 | 34,561 | N/A |
3/31/2018 | 224,942 | 35,247 | 32,906 | 42,843 | N/A |
12/31/2017 | 217,021 | 30,580 | N/A | 39,581 | N/A |
9/30/2017 | 212,041 | 25,717 | N/A | 37,624 | N/A |
6/30/2017 | 205,038 | 24,756 | N/A | 30,180 | N/A |
3/31/2017 | 199,096 | 23,061 | N/A | 10,843 | N/A |
12/31/2016 | 196,754 | 23,299 | N/A | 4,869 | N/A |
9/30/2016 | 195,247 | 22,317 | N/A | 5,091 | N/A |
6/30/2016 | 197,322 | 53,155 | N/A | 8,601 | N/A |
3/31/2016 | 195,291 | 53,373 | N/A | 22,525 | N/A |
12/31/2015 | 194,193 | 57,729 | N/A | 29,919 | N/A |
9/30/2015 | 187,779 | 58,590 | N/A | 34,513 | N/A |
6/30/2015 | 176,124 | 27,842 | N/A | 30,263 | N/A |
3/31/2015 | 161,831 | 24,032 | N/A | 25,386 | N/A |
12/31/2014 | 156,559 | 17,923 | N/A | 23,350 | N/A |
9/30/2014 | 151,325 | 17,214 | N/A | 17,923 | N/A |
6/30/2014 | 148,031 | 15,278 | N/A | 19,086 | N/A |
3/31/2014 | 148,663 | 17,109 | N/A | 25,958 | N/A |
12/31/2013 | 139,587 | 17,760 | N/A | 19,774 | N/A |
9/30/2013 | 131,614 | 16,536 | N/A | 16,873 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4536's forecast earnings growth (8.3% per year) is above the savings rate (0.2%).
Earnings vs Market: 4536's earnings (8.3% per year) are forecast to grow slower than the JP market (8.9% per year).
High Growth Earnings: 4536's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4536's revenue is expected to decline over the next 3 years (-1.8% per year).
High Growth Revenue: 4536's revenue is forecast to decline over the next 3 years (-1.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4536's Return on Equity is forecast to be low in 3 years time (10.3%).